Azura Ophthalmics

Two biotechs target dry eye disease after Novartis’ Xiidra problems
Pharmaforum
Thu, 03/4/21 - 09:57 am
dry eye disease
Novartis
Xiidra
Sylentis
Azura Ophthalmics
Azura Ophthalmics gets a $20M boost for its R&D work on eye diseases
Endpoints
Thu, 10/22/20 - 11:09 am
Azura Ophthalmics
R&D
eye diseases